Clinical Trial

Photobiomodulation Therapy in the Management of Chemotherapy-Induced Peripheral Neuropathy

Study acronym: NeuroLight 2
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 30, 2023 (before its estimated March 15, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study aims to investigate the effectiveness of photobiomodulation therapy (PBM) in the management of chemotherapy-induced peripheral neuropathy (CIPN). Therefore, the hypothesis is that PBM can reduce the severity of CIPN in cancer patients, increasing the patient's quality of life.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2023-02-28.
Status change: Not Yet Recruiting → Recruiting 2023-03-28
Trial Details
NCT Number NCT05763706
Lead Sponsor Jessa Hospital
Conditions Chemotherapy-induced Peripheral Neuropathy
Enrollment 172 participants
Start Date 2023-03-27
Primary Completion 2025-03-15 (estimated)
Study Completion 2030-03-15 (estimated)
Updated on ClinicalTrials.gov 2023-03-30